Literature DB >> 7617523

Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo.

T Tokui1, N Maeda, C Kuroiwa, K Sasagawa, T Inoue, K Kawai, T Ikeda, T Komai.   

Abstract

RS-1541 is a 13-O-palmitoyl derivative of rhizoxin, an inhibitor of tubulin polymerization. After intravenous administration of RS-1541 to mice bearing M5076 sarcoma, the maximal inhibitory effect of RS-1541 on DNA synthesis in the tumor was observed 24 h after administration, in agreement with the Cmax of rhizoxin produced from RS-1541, but not with the Cmax of RS-1541. The inhibitory effect after RS-1541 was much higher than that after rhizoxin itself. In the spleen, thymus and bone marrow, DNA synthesis was strongly inhibited by rhizoxin but not by RS-1541. After administration of RS-1541, no significant amounts of rhizoxin were detected in the tissues, except for the tumor. In acute toxicity tests, RS-1541 appeared to be less toxic than rhizoxin. These results indicate that RS-1541 possesses a high tumor-selective effect compared with rhizoxin, because of the selective production of rhizoxin in the tumor after administration of RS-1541.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617523     DOI: 10.1023/a:1016248417492

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

2.  Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells.

Authors:  S Ozawa; Y Sugiyama; J Mitsuhashi; M Inaba
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

3.  Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.

Authors:  T C Chou; D J Hutchinson; F A Schmid; F S Philips
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

4.  Rhizoxin binding to tubulin at the maytansine-binding site.

Authors:  M Takahashi; S Iwasaki; H Kobayashi; S Okuda; T Murai; Y Sato
Journal:  Biochim Biophys Acta       Date:  1987-12-07

5.  Studies on macrocyclic lactone antibiotics. VII. Structure of a phytotoxin "rhizoxin" produced by Rhizopus chinensis.

Authors:  S Iwasaki; H Kobayashi; J Furukawa; M Namikoshi; S Okuda; Z Sato; I Matsuda; T Noda
Journal:  J Antibiot (Tokyo)       Date:  1984-04       Impact factor: 2.649

6.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

7.  Delivery and cytotoxicity of RS-1541 in St-4 human gastric cancer cells in vitro by the low-density-lipoprotein pathway.

Authors:  T Tokui; T Takatori; N Shinozaki; M Ishigami; A Shiraishi; T Ikeda; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Contribution of serum lipoproteins as carriers of antitumour agent RS-1541 (palmitoyl rhizoxin) in mice.

Authors:  T Tokui; C Kuroiwa; Y Tokui; K Sasagawa; K Kawai; T Kobayashi; T Ikeda; T Komai
Journal:  Biopharm Drug Dispos       Date:  1994-03       Impact factor: 1.627

9.  Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues.

Authors:  M Takahashi; S Iwasaki; H Kobayashi; S Okuda; T Murai; Y Sato; T Haraguchi-Hiraoka; H Nagano
Journal:  J Antibiot (Tokyo)       Date:  1987-01       Impact factor: 2.649

10.  Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines.

Authors:  T Tsuruo; T Oh-hara; H Iida; S Tsukagoshi; Z Sato; I Matsuda; S Iwasaki; S Okuda; F Shimizu; K Sasagawa
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.